Date:Aug 26, 2021
Your Name:Chelsie Armbruster
Manuscript Title:_Prospective assessment of catheter-associated bacteriuria in nursing home residents: clinica
presentation, epidemiology, and colonization dynamics
Manuscript number (if known): 144775-INS-CMED-1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	
1	All support for the present	None	R00 DK105205, R01 DK123158, UL1 TR001412
	manuscript (e.g., funding,	NIH	
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
	ino time illint for this item.		
		Time frame, past	26 months
2	Grants or contracts from	Time frame: past	50 Months
2	any entity (if not indicated	x None	
	in item #1 above).		
3	Royalties or licenses	x None	
	The facilities of meetinges		

4	Consulting fees	x None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None Western New York branch, American Society for Microbiology	Honorarium for presentation at annual meeting
6	Payment for expert testimony	x None	
7	Support for attending meetings and/or travel	x None	
8	Patents planned, issued or pending	x None	
9	Participation on a Data Safety Monitoring Board or	x None	
	Advisory Board		
10	Landarship or fiducianu rala	y None	
10	Leadership or fiduciary role in other board, society,	x None	
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	x None	
	occord occord options	_^	
12	Receipt of equipment, materials, drugs, medical	x None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	x None	

Date	e:Aug 26, 2021			
	Your Name:Aimee Brauer			
Mar	Manuscript Title:_Prospective assessment of catheter-associated bacteriuria in nursing home residents: clinical			
pres	entation, epidemiology, an	d colonization dynamics		
Mar	nuscript number (if known):	144775-INS-CMED-1		
relate part to tr	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.			
	The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u> .			
to th	The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.			
	In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items the time frame for disclosure is the past 36 months.			
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed)		
		Time frame: Since the initial	planning of the work	
1	All support for the present	x None		
	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
		Time frame: past	36 months	
2	Grants or contracts from	x None		
	any entity (if not indicated in item #1 above).			

__x__ None

3

Royalties or licenses

4	Consulting fees	x None	
5	Payment or honoraria for lectures, presentations,	x None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert testimony	x None	
7	Support for attending meetings and/or travel	x None	
8	Patents planned, issued or pending	x None	
9	Participation on a Data Safety Monitoring Board or	x None	
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	x None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	x None	
12	Receipt of equipment, materials, drugs, medical	x None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	x None	

Date	e:Aug 26, 2021				
	Your Name:Monica Humby				
	Manuscript Title:_Prospective assessment of catheter-associated bacteriuria in nursing home residents: clinical				
-					
Man	Manuscript number (if known):144775-INS-CMED-1				
relat part to tr	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.				
	The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.				
to th	The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.				
In item #1 below, report all support for the work reported in this manuscript without time limit. For all other iten the time frame for disclosure is the past 36 months.					
		Name all entities with	Specifications/Comments		
		whom you have this	(e.g., if payments were made to you or to your		
		relationship or indicate	institution)		
		none (add rows as			
		needed)			
		Time frame: Since the initial	planning of the work		
1	All support for the present	x None			
	manuscript (e.g., funding,				
	provision of study materials, medical writing, article				
	processing charges, etc.)				
	No time limit for this item.				
		Time frame: past	36 months		
2	Grants or contracts from	x None			
	any entity (if not indicated				
	in item #1 above).				

__x__ None

Royalties or licenses

5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board X_ None	4	Consulting fees	x None	
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or				
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or				
manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	5	lectures, presentations,	x None	
educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Safety Monitoring Board or A None				
testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or		educational events		
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	6		x None	
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or				
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or				
9 Participation on a Data Safety Monitoring Board or	7		x None	
9 Participation on a Data Safety Monitoring Board or		_		
9 Participation on a Data Safety Monitoring Board or				
Safety Monitoring Board or	8		x None	
Safety Monitoring Board or				
Safety Monitoring Board or				
Advisory Board	9		x None	
		Advisory Board		
10 Leadership or fiduciary rolex_ None in other board, society,	10		x None	
committee or advocacy				
group, paid or unpaid				
11 Stock or stock optionsx_ None	11	Stock or stock options	x None	
12 Receipt of equipment,x None materials, drugs, medical	12	1	x None	
writing, gifts or other				
services				
13 Other financial or non- financial interestsx None	13		x None	

Date: Aug 26, 2021	
Your Name: Jiahui Shao	
Manuscript Title:_Prospective assessment of catheter-associated bacteriuria in nursing presentation, epidemiology, and colonization dynamics	home residents: clinical
Manuscript number (if known):144775-INS-CMED-1	
In the interest of transparency, we ask you to disclose all relationships/activities/interested to the content of your manuscript. "Related" means any relation with for-profit parties whose interests may be affected by the content of the manuscript. Disclosure r	t or not-for-profit third

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a

relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
			planning of the work
1	All support for the present	x None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	x None	
	in item #1 above).		
	,		
3	Royalties or licenses	x None	

5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board X_ None	4	Consulting fees	x None	
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or				
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or				
manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	5	lectures, presentations,	x None	
educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Safety Monitoring Board or A None				
testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or		educational events		
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	6		x None	
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or				
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or				
9 Participation on a Data Safety Monitoring Board or	7		x None	
9 Participation on a Data Safety Monitoring Board or		_		
9 Participation on a Data Safety Monitoring Board or				
Safety Monitoring Board or	8		x None	
Safety Monitoring Board or				
Safety Monitoring Board or				
Advisory Board	9		x None	
		Advisory Board		
10 Leadership or fiduciary rolex_ None in other board, society,	10		x None	
committee or advocacy				
group, paid or unpaid				
11 Stock or stock optionsx_ None	11	Stock or stock options	x None	
12 Receipt of equipment,x None materials, drugs, medical	12	1	x None	
writing, gifts or other				
services				
13 Other financial or non- financial interestsx None	13		x None	

Date:Aug 26, 2021
Your Name:Saptarshi Chakraborty
Manuscript Title:_Prospective assessment of catheter-associated bacteriuria in nursing home residents: clinical presentation, epidemiology, and colonization dynamics
Manuscript number (if known):144775-INS-CMED-1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
			planning of the work
1	All support for the present	x None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	x None	
	in item #1 above).		
	,		
3	Royalties or licenses	x None	

S Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board	4	Consulting fees	x None	
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or				
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or				
manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	5	lectures, presentations,	x None	
educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Safety Monitoring Board or A None				
testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or		educational events		
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or	6		x None	
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or				
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or				
9 Participation on a Data Safety Monitoring Board or	7		x None	
9 Participation on a Data Safety Monitoring Board or		-		
9 Participation on a Data Safety Monitoring Board or				
Safety Monitoring Board or	8		x None	
Safety Monitoring Board or				
Safety Monitoring Board or				
Advisory Board	9		x None	
		Advisory Board		
10 Leadership or fiduciary rolex_ None in other board, society,	10		x None	
committee or advocacy				
group, paid or unpaid				
11 Stock or stock optionsx_ None	11	Stock or stock options	x None	
12 Receipt of equipment,x None materials, drugs, medical	12		x None	
writing, gifts or other		= =		
services				
13 Other financial or non- financial interestsx None	13		x None	

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	
		(b) Provide in the abstract an informative and balanced summary of what was done	
		and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	
Methods			
Study design	4	Present key elements of study design early in the paper	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment,	
C		exposure, follow-up, and data collection	
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of	
-		participants. Describe methods of follow-up	
		(b) For matched studies, give matching criteria and number of exposed and	
		unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect	
		modifiers. Give diagnostic criteria, if applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of methods of	
measurement		assessment (measurement). Describe comparability of assessment methods if there is	
		more than one group	
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable,	
		describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) If applicable, explain how loss to follow-up was addressed	
		(e) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially	
		eligible, examined for eligibility, confirmed eligible, included in the study,	
		completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and	
		information on exposures and potential confounders	
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	Report numbers of outcome events or summary measures over time	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and	
		their precision (eg, 95% confidence interval). Make clear which confounders were	
		adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a	
		meaningful time period	

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and
		sensitivity analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or
		imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations,
		multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	Discuss the generalisability (external validity) of the study results
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if
		applicable, for the original study on which the present article is based

^{*}Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.